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Fatty acid oxidation is required for the respiration  
and proliferation of malignant glioma cells
Glioma is the most common form of primary malignant 
brain tumor in adults. In >50% of cases, this tumor mani-
fests as a grade IV astrocytoma (called glioblastoma or 
GBM), a highly malignant and invasive tumor with median 
patient survival of 12 months from diagnosis.1 Lower-grade 
gliomas increase in malignancy over time, with associated 
increases in mortality.2 There are no major heritable factors 
in the risk of glioma occurrence, and treatments including 
surgical resection, radiotherapy, and the chemotherapeutic 
drug temozolomide only minimally slow the course of this 
disease. There is a great need to develop novel targets for 
therapeutic intervention.
In the 1950s, Otto Warburg observed that tumors primar-
ily metabolized glucose; instead of using the end product 
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Abstract
Background. Glioma is the most common form of primary malignant brain tumor in adults, with approximately 4 
cases per 100 000 people each year. Gliomas, like many tumors, are thought to primarily metabolize glucose for 
energy production; however, the reliance upon glycolysis has recently been called into question. In this study, we 
aimed to identify the metabolic fuel requirements of human glioma cells.
Methods. We used database searches and tissue culture resources to evaluate genotype and protein expression, 
tracked oxygen consumption rates to study metabolic responses to various substrates, performed histochemical 
techniques and fluorescence-activated cell sorting-based mitotic profiling to study cellular proliferation rates, and 
employed an animal model of malignant glioma to evaluate a new therapeutic intervention.
Results. We observed the presence of enzymes required for fatty acid oxidation within human glioma tissues. In 
addition, we demonstrated that this metabolic pathway is a major contributor to aerobic respiration in primary-
cultured cells isolated from human glioma and grown under serum-free conditions. Moreover, inhibiting fatty acid 
oxidation reduces proliferative activity in these primary-cultured cells and prolongs survival in a syngeneic mouse 
model of malignant glioma.
Conclusions. Fatty acid oxidation enzymes are present and active within glioma tissues. Targeting this metabolic 
pathway reduces energy production and cellular proliferation in glioma cells. The drug etomoxir may provide 
therapeutic benefit to patients with malignant glioma. In addition, the expression of fatty acid oxidation enzymes 
may provide prognostic indicators for clinical practice.
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(pyruvate) to drive oxidative metabolism, the cells con-
verted pyruvate into lactate and released it into the extra-
cellular space. This dependence upon glycolysis instead of 
oxidative metabolism, (known as the Warburg effect) was 
first characterized in sarcomas and later shown in other 
cancers.3 Warburg hypothesized that this glycolytic switch 
was the initiating event during oncogenic transformation. 
Although it is now understood that cancers arise from 
genetic abnormalities affecting oncogene and tumor sup-
pressor pathways, the possibility remains that targeting 
catabolic pathways required for cellular energy produc-
tion may be a fruitful clinical strategy.
Like other tumors, gliomas have been thought to rely 
upon glycolysis for energy production, yet recent results 
from human NMR spectroscopy studies suggest that glu-
cose contributes to <50% of acetyl-CoA production in glio-
mas.4 While the metabolic substrates preferred by these 
tumors have not been identified, other cancers have been 
shown to utilize alternative fuels for energy production 
and synthesis of raw materials.5 Fatty acid chains can be 
used to produce energy within a growing tumor;6 prostate 
and breast cancer cells in particular have been specifically 
shown to employ fatty acid oxidation as a metabolic strat-
egy.7,8 Etomoxir, an inhibitor of fatty acid oxidation, has 
been shown to decrease oxygen consumption rates (OCRs) 
and impair ATP and NADPH production in the pediatric 
glioblastoma cell line SF188.9 Various substrates, including 
glucose, can be converted into fatty acids intracellularly; 
gliomas express fatty acid synthase (FASN), and expres-
sion of this enzyme increases with malignant grade.10
High levels of glycolysis have been primarily reported 
based upon the study of glioma cell lines that have 
adapted to culture conditions. It has recently been shown 
that patient-derived glioma cells cultured in the absence 
of serum retain their original characteristics and are more 
suitable for chemical and genetic screening.11,12 In this 
report, we show that fatty acid oxidation is in fact the 
primary catabolic pathway in human glioblastoma cells 
(hGBMs) maintained under such optimal culture condi-
tions. Blocking this pathway reduces cellular respiratory 
and proliferative activity. Enzymes required for fatty acid 
oxidation are expressed and functional in human glio-
blastoma tissues, and upregulation of genes encoding 
enzymes in this pathway predicts worse survival in human 
patients with astrocytoma (although this effect is not sig-
nificant in high-grade glioblastoma). Finally, we show that 
pharmacological inhibition of fatty acid oxidation pro-
longs survival in a syngeneic mouse model of malignant 
glioma in the context of a blinded, placebo-controlled pre-
clinical trial. These findings present a new target that may 
aid in the clinical treatment of this disease.
Materials and Methods
REMBRANDT Database Search
Comparisons of patient survival on the basis of genotype 
were performed using 2 databases: the REpository of 
Molecular BRAin Neoplasia DaTa (REMBRANDT) and The 
Cancer Genome Atlas (TCGA), which provide coordinated 
molecular genetic data and clinical data from patients with 
brain tumors.13,14 All genes encoding enzymes in the fatty 
acid oxidation pathway were searched (Supplementary 
material, Table S1). Data mining and statistical analysis 
were performed with Project Betastasis software (http://
www.betastasis.com/glioma/). Significant results yielded 
by Kaplan-Meier survival tests are reported as log-ranked 
P values for significance of difference in survival between 
groups. Previously published clinical and microarray data 
for low-grade glioma from the TCGA database14 were 
downloaded from https://genome-cancer.soe.ucsc.edu/
proj/site/hgHeatmap/?datasetSearch=low+grade+gliom
a+TCGA, and specific transcripts were analyzed by 1-way 
ANOVA in SigmaPlot. Median gene expression level was 
used as the cutoff for comparing clinical outcomes.
Immunohistochemistry
All tissues were obtained with consent from patients 
under approval from Newcastle upon Tyne Hospitals NHS 
Foundation Trust. Twenty-eight samples identified as glio-
blastomas on the basis of clinical presentation and his-
tological analysis were employed to investigate protein 
expression levels. Formalin-fixed, paraffin-embedded 
tissue blocks were obtained from the Cellular Pathology 
Department at the Royal Victoria Infirmary in Newcastle. 
Blocks were sectioned into 5 µm and dried overnight. The 
sections were placed in a 60°C oven for 30 minutes, moved 
directly into Histoclear, and then hydrated in decreasing 
concentrations of ethanol.
For antigen retrieval, cells were subjected to 0.01 M 
sodium citrate at 100°C for 10 minutes. Sections were then 
rinsed with phosphate-buffered saline (PBS). Nonspecific 
staining was blocked for 2 hours in PBS with 0.1% Triton 
X-100 and 5% donkey serum. Sections were incubated 
overnight at 4°C with appropriate primary antibodies and 
for 2 hours at room temperature with secondary antibod-
ies (Supplementary material, Table S2). Sections were 
then co-stained with 1  µg/mL Hoechst. Coverslips were 
mounted over sections, and fluorescence microscopy 
was performed using a Zeiss Apoptome microscope with 
attached camera and Axiovision software.
Serum-free Primary Culture of hGBMs
hGBMs G144, G166, and GliNS2, which had been origi-
nally cultured in the lab of Professor Austin Smith, were 
obtained from a BioRep cryogenic storage facility (Milan, 
Italy). The cells were maintained in sterile, serum-free cul-
ture in NeuroCult Basal Medium (Stem Cell Technologies 
05750) with NeuroCult Proliferation Supplement (Stem Cell 
Technologies 05753). NeuroCult Proliferation Medium was 
supplemented with 20 ng/mL bFGF (Peprotech 100-18) and 
20 ng/mL EGF (Peprotech 100-15). This complete medium 
was used as the growth medium for cell culture. Cells 
were passaged every 4 days by dissociating with Accutase 
(Sigma A6964). In vitro experiments were performed with 
all 3 biological replicates. Fluorescence-activated cell 
sorting (FACS)-based mitotic profiling contained 6 techni-
cal replicates for each biological replicate, and Seahorse 
Analyzer experiments contained 5 technical replicates for 
each biological replicate.
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Serum-free Primary Culture of Oncogenically 
Transformed Mouse NSCs
Neural stem cells (NSCs) were isolated from the adult wild-
type C57B/6 mouse brain as previously described.15 The 
cells were oncogenically transformed in vitro as previously 
described.16 These glioma-initiating cells were maintained 
in serum-free growth media consisting of Dulbecco's mod-
ified Eagle's medium/F12 (Omega Scientific DM-25) sup-
plemented with 2 mM glutamine, 1% N2 (Gibco), 20 ng/mL 
epidermal growth factor, and 20 ng/mL fibroblast growth 
factor-2 (Peprotech). In vitro experiments were performed 
with 3 biological replicates (each with 10 technical repli-
cates) except for Seahorse Analyzer experiments, which 
were performed with 3 biological replicates (each with 5 
technical replicates).
Extracellular Flux Analysis in Live Cells
OCRs were measured using the Seahorse XF24 
Extracellular Flux Analyzer as described.17 hGBM cells, 
and oncogenically transformed mouse NSCs were plated 
in XF24 cell culture plates (Seahorse Bioscience) at 10^5 
cells/well and incubated for 72 hours at 37°C with 5% CO2. 
One row of cells contained 10% fetal bovine serum (FBS). 
On the day of experimentation, each well was replaced 
with bicarbonate-free low-buffered medium (Seahorse 
Bioscience) with the following: no supplement, 5 mM glu-
cose, 2 mM L-glutamine, or 1% FBS. Cells were incubated 
for 1 hour at 37°C with 0% CO2. Each time point included 
5 minutes of rest, 1 minute of mixing, and 3 minutes of 
measuring. OCR measurements were normalized to cell 
counts and then compared using 2-tailed t tests in Excel. 
A similar protocol was used to evaluate cellular responses 
to 5 mM glucose and 5 mM 2-deoxyglucose (2-DG).
Analysis of Cellular Proliferation and Viability
To quantify the fractions of actively cycling cells in the 
population, we employed 2 methods: immunocytochemi-
cal labeling of KI67 and FACS-based mitotic profiling. 
For KI67 labeling, 13  mm glass coverslips were placed 
in 24-well plates and coated with 10  µg/mL laminin in 
Dulbecco's phosphate buffered saline (dPBS) for 2 hours 
at 37°C. hGBM cells were plated at a density of 10 000 cells 
per well on coated glass coverslips for 24 hours in growth 
medium. Cells were then treated with 10  µL of dPBS, 
5 mM etomoxir, or 5 mM linoleic acid for a final concen-
tration of 100  µM etomoxir (Sigma E1905) and 100  µM 
linoleic acid (Sigma L1376). Twenty-four hours after treat-
ment, cells were fixed in 4% paraformaldehyde. Coverslips 
with attached cells were subjected to immunohistochemi-
cal staining as described above. In a separate experiment, 
TdT+ apoptotic cells were quantified using an enzymatic 
detection kit as directed (Chemicon S7160).
To perform mitotic profiling, hGBM cells were treated 
with dPBS, etomoxir, or linoleic acid. Twenty-four hours 
after treatment, cells were labelled with 2 µg/mL Hoechst 
in permeabilization solution and then subjected to FACS 
using LSRII equipment and ModFit software for mitotic 
profile analysis. For each experimental assay, each of 3 
biological replicates was plated in triplicate for each treat-
ment group. Groups were compared using 2-tailed t tests 
in Excel.
Inhibition of Fatty Acid Oxidation in Vivo
To assess the efficacy of inhibiting fatty acid oxidation in 
slowing tumor growth in vivo, we performed a blinded, 
placebo-controlled preclinical study in a mouse model of 
malignant glioma. All work on animals was performed in 
line with Home Office licensing. NSCs isolated from the 
adult mouse brain were oncogenically transformed in vitro 
(as described above) and then transplanted into the brain 
tissue of wild-type mice of the same genetic background (a 
syngeneic model). A total of 10^4 cells in 1 microliter were 
injected across 2 sites within striatum: AP + 1.0, ML −1.5, 
DV −3.5, and DV −3.0. Fourteen days after intracranial cell 
implantation, osmotic pumps were implanted subcutane-
ously. Pumps were loaded with either saline alone or 50 
mg/mL etomoxir sodium-salt (Sigma E1905) in saline to 
achieve approximately 10 mg/kg of drug treatment per day. 
Once euthanasia criteria were reached, animals were tran-
scardially perfused with 4% paraformaldehyde. Survival 
curves were compared between treatment groups using 
ANOVA in Prism.
Tissues were sectioned into 16 μm-thick slices for stain-
ing procedures. Tissues from all 26 animals were assessed 
by hemotoxylin & eosin (H&E) to confirm the presence of 
tumor, using an Olympus microscope with attached cam-
era. For protein expression analysis (n = 9 animals per treat-
ment group), immunohistochemistry was performed as 
described above. Fluorescence microscopy was performed 
using a Zeiss Apoptome microscope with attached camera 
and Axiovision software. Protein expression levels were 
compared between groups using 2-tailed t tests in Excel.
For MRI, mice were anesthetized by isoflurane/oxygen 
inhalation and imaged using the Rapid 33  mm volume 
coil with SA Instruments’ physiological monitoring sys-
tem to maintain temperature and measure respiration. 
Parameters for the gradient echo multislice scan (GEMS) 
were: repetition time (TR) 500 ms, effective echo time (TE) 
5.54 ms, matrix 256 × 256, field of view 20 × 20 mm, flip 
angle 20°, and slice thickness 1 mm, giving a T1 weighted 
sequence. The software Vnmr J (Varian/Agilent) Version 
3.1A was used to calculate tumor volumes. One animal 
from each group was scanned.
Results
Expression of Fatty Acid Oxidation Enzymes in 
Human Glioma Tissues
We evaluated expression of enzymes involved in fatty 
acid oxidation in 28 samples of fixed human glioblas-
toma tissue (Fig.  1). Acyl-CoA dehydrogenases such as 
medium-chain acyl-CoA dehydrogenase (MCAD), which 
catalyzes the first oxidation step of fatty acids in the cata-
bolic pathway, were observed in a fraction of cells in all 
tumor samples studied with variability between individu-
als (Figs 1 A–C and 2 W). Carnitine palmitoyl transferase 
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Fig. 1 Human glioblastomas express enzymes required for fatty acid oxidation. Representative photomicrographs 
demonstrate staining in human glioblastoma tissue for medium-chain acyl-CoA dehydrogenase (MCAD, A), short-
chain hydroxyacyl CoA dehydrogenase (SCHAD, B), very-long-chain acyl-CoA dehydrogenase (VLCAD, C), carnitine 
palmitoyl transferase 1a (CPT1a, D), and the trifunctional protein hydroxyacyl-CoA dehydrogenase/3-ketoacyl-CoA 
thiolase/enoyl-CoA hydratase (HADHA, E). The majority of mitochondria labeled with the pan-mitochondrial marker 
succinate dehydrogenase (SDHA) are co-labeled with HADHA (F-J). A fraction of cells in human glioblastoma tissue 
identified with Hoechst (K,O,S) and expressing MCAD (L,P,T) co-label with the astroglial marker GFAP (M), the neural 
progenitor marker SOX2 (Q), and the glial progenitor marker OLIG2 (U). Representative abeled cells are shown in 
merged images (N,R,V). The fraction of cells expressing each of the fatty acid oxidation enzymes is shown (W), as 
well as the fraction of total cells (X) and MCAD+ cells (Y) co-labeled with each cell type. Scale bars are 10 µm.
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Fig. 2 Fatty acid oxidation is a primary contributor to aerobic respiration in primary-cultured hGBMs. The oxygen 
consumption rate (OCR) of primary-cultured serum-free hGBM cells was assessed using the Seahorse Analyzer (A). 
Baseline measurements were taken for cells in plain medium (empty circles), with glutamine (black triangles), with 
glucose (black squares), and exposed to 10% FBS for 72 hours prior to the experiment (grey diamonds). Cells were 
then treated with 100 µM linoleic acid (a polyunsaturated fatty acid), 100 µM etomoxir (an inhibitor of beta-oxida-
tion), 2.0 µM FCCP (which induces maximal respiration), and 2.5 µM antimycin A (which inhibits aerobic respiration). 
Spare respiratory capacity, calculated by dividing basal OCR by maximal OCR, is shown (B). Cellular response to 
linoleic acid (light grey bars) and etomoxir (dark grey bars) is shown (C). The fraction of mitochondrial respiration 
dependent on fatty acids is shown (D). A similar experiment was conducted to evaluate responses to glucose and 
the glycolytic inhibitor 2-DG (E). Cellular responses are summarized (F), and the fraction of mitochondrial respiration 
dependent on glucose oxidation or glycolysis is shown (G). *indicates significant change in respiration, P < .05.
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1a (CPT1a), which transports fatty acids across the mito-
chondrial membrane to be oxidized, and the trifunctional 
protein hydroxyacyl-CoA dehydrogenase/3-ketoacyl-CoA 
thiolase/enoyl-CoA hydratase (HADHA), which catalyzes 
the final 3 steps in beta-oxidation, were also observed in 
all tumors (Fig. 1 D and E). A schematic showing each of 
the enzymes in this biochemical pathway is provided 
(Supplementary material, Fig. S1). Expression of enzymes 
in this pathway is not correlated with age or radiother-
apy treatment (Supplementary material, Figs S2 and S3). 
Expression of the 3 acyl-CoA-dehydrogenase enzymes is 
correlated within individual glioblastomas, and MCAD 
expression is negatively correlated with tumor cell density 
(Supplementary material, Fig. S4).
The enzymes appear to be localized to the mitochondria. 
Nearly all cells expressing the pan-mitochondrial marker 
succinate dehydrogenase (SDHA) express the fatty acid 
oxidation enzyme HADHA; these markers show strong co-
labeling (Fig. 1 F–J). Mitochondria occasionally appeared 
not as puncta but as chains throughout the cytoplasm, as 
has been reported in other proliferative cell types.18
To identify the cell types within human glioblastoma 
tissue that are engaging in fatty acid oxidation, we cola-
beled the enzyme MCAD with cell type-specific antibodies, 
including the astroglial marker GFAP, the neural progeni-
tor marker SOX2, and the glial progenitor marker OLIG2 
(Fig. 1 K–V). MCAD is expressed in OLIG2+ cells to a greater 
extent than GFAP+ or SOX2+ (Fig. 1 X and Y), although this 
enzyme is present in multiple cell types within human glio-
blastoma tissue.
Differential Gene Expression and Survival Time 
in Human Glioma Patients
We next performed statistical analysis of glioma patient 
survival on the basis of gene expression.13,14 Kaplan-Meier 
survival plots were produced to compare survival among 
genetically defined glioma patients (Supplementary mate-
rial, Fig. S5), particularly focusing on genes encoding fatty 
acid oxidation enzymes. We found that upregulation of 4 
genes (of 9 total) in this metabolic pathway was associated 
with significantly worse survival in patients with low-grade 
astrocytoma (in both the REMBRANDT and TCGA data-
bases). No significant differences in survival time for GBM 
patients were observed in either database.
Metabolic Fuel Requirements of Primary-Cultured 
Human Glioma Cells
To determine whether fatty acid oxidation enzymes 
expressed in brain tumor tissues are functional, further 
analysis was performed on primary-cultured hGBMs 
expanded under serum-free conditions.12 All experiments 
contained averaged data from 3 cultures: G144, G166, and 
GliNS2. The OCRs of these precharacterized cells were 
measured using the Seahorse Extracellular Flux Analyser.17 
Cells were treated first with linoleic acid, a polyunsaturated 
fatty acid, then with etomoxir, an inhibitor of carnitine pal-
mitoyl transferase I (the rate-limiting enzyme in fatty acid 
oxidation). The addition of linoleic acid stimulates OCR 
in hGBMs even in the presence of glucose or glutamine 
(Fig. 2 A–D). Cells also decrease OCRs in response to eto-
moxir, although this response is blunted in cells exposed 
to serum for 3 days (Fig. 2 C and D). A similar experiment 
was conducted on mouse glioma-initiating cells (NSCs). 
NSCs were isolated from normal adult wild-type mice and 
primary-cultured under serum-free conditions in vitro and 
then transformed oncogenically by introduction of several 
clinically relevant genetic lesions to reproduce the molecu-
lar and phenotypic characteristics of glioma. In these cells, 
linoleic acid significantly increased OCR; etomoxir had no 
effect in this experiment, either because cells switched to 
using glucose or because the mitochondria had already 
acquired sufficient fatty acids to supply the fatty acid oxida-
tion pathway (Supplementary material, Fig. S6A–D).
The response of primary-cultured hGBMs to glucose 
and the glycolytic inhibitor 2-deoxyglucose (2-DG) was 
also tested using the Seahorse Analyzer. 2-DG significantly 
decreases OCR in non-serum-exposed cells, suggesting 
that glucose or its derivatives are otherwise being oxidized 
(Fig.  2 E–G). Meanwhile, glucose treatment significantly 
decreased OCR in serum-exposed cells, indicating a prefer-
ence for anaerobic respiration when substrates are avail-
able (Fig. 2 E–G). A similar experiment was conducted on 
the mouse glioma-initiating cells (Supplementary material, 
Fig. S6E–G). Without serum exposure, these cells did not 
respond to either glucose or 2-DG. After serum exposure, 
however, these cells increased OCR in response to 2-DG.
The Role of Fatty Acid Oxidation in the 
Proliferation of Human Glioma Cells
To test whether fatty acid oxidation plays a role in cellu-
lar survival and proliferation, serum-free primary-cultured 
hGBMs were subjected to analysis after treatment with 
vehicle control, 100 µM etomoxir sodium salt, or 100 µM 
linoleic acid (Fig. 3 A–M). Etomoxir decreased KI67+ index, 
total cell count, and the fraction of cells in S+G2/M phase 
of the cell cycle, suggesting that this energy-producing 
biochemical pathway is important for the proliferation of 
human glioma cells. Inhibition of fatty acid oxidation with 
etomoxir also reduces proliferation and viability of mouse 
glioma-initiating cells (Supplementary material, Fig. S7).
Inhibiting Fatty Acid Oxidation in a Mouse Model 
of Malignant Glioma
To evaluate the efficacy of etomoxir in slowing tumor 
growth in vivo, we employed a mouse model of malignant 
glioma. The oncogenically transformed mouse NSCs used 
in the experiments described above were transplanted into 
immunocompetent wild-type mice of the same genetic 
background (a syngeneic model). This process reliably 
forms a high-grade glial tumor that reproduces the histo-
logical and clinical characteristics of human glioma.
A blinded, placebo-controlled preclinical study was con-
ducted to evaluate the efficacy of slowing glioma growth 
in vivo with etomoxir treatment. Fourteen days after cell 
implantation, when animals had only small regions of dys-
plasia, osmotic pumps were implanted to deliver drug or 
saline vehicle control for 30 days (Fig. 4 A). Animal weight 
and behavior were monitored daily until euthanasia criteria 
49Lin et al. Fatty acid metabolism in malignant glioma cells
N
eu
ro-
O
n
colog
y
were reached (Supplementary material, Fig. S8), where-
upon animals were found to have high-grade glial tumors. 
Mice in both treatment groups exhibited largely similar 
clinical symptoms during the last week of life leading up 
to clinical endpoint (Fig. 4 B, Supplementary material, Fig. 
S9). However, mice treated with 10 mg/kg etomoxir sodium 
salt survived significantly longer than their saline-treated 
cage mates (Fig. 4 C, Supplementary material, Table S3).
Upon tissue collection, brains were photographed to 
evaluate tumor severity on a macro scale; no differences 
in tumor size were observed between treatment groups 
at clinical endpoint, a finding that was subsequently con-
firmed by histopathological evaluation of H & E stained 
sections (Fig.  5 A–C). Sections from all animals were 
subjected to H & E staining procedures to assess tumor 
infiltration patterns throughout the brain and were not sig-
nificantly different between treatment groups (Fig. 5 D–J). 
The postmortem tissues were evaluated by extrapolating 
criteria for human intracranial tumor grading set out by the 
2007 WHO guidelines. The tumors were identified as high-
grade anaplastic astrocytoma. Stereotypical reproduction 
of histological features was observed between animals at 
Fig. 3 Inhibition of fatty acid oxidation decreases proliferation in hGBMs but does not affect cellular survival. Sample 
photomicrographs of cells treated with phosphate-buffered saline (PBS) (A, D), 100 µM etomoxir (B, E), or 100 µM 
linoleic acid (C, F) are shown, stained with either TdT, a marker of apoptosis (A–C), or KI67, an S-phase cell cycle 
marker (D–F). Separate channels are shown to display Hoechst, a pan-nuclear marker ('), and TdT or KI67 (''). The frac-
tion of TdT+ apoptotic cells did not change significantly in either treatment group (P > .05, G). The fraction of KI67+ 
proliferating cells decreased upon 24 hours treatment with etomoxir (P < .05, H) and increased upon 24 hours of 
treatment with linoleic acid (P < .01, H). The total cell count after 24 hours was significantly decreased in the presence 
of etomoxir (P < .01, I) but was unaffected in the presence of linoleic acid (P > .05, I). Shown are representative data 
from fluorescence-activated cell sorting-based analysis of the mitotic index of primary-cultured serum-free hGBM 
cells, performed after treatment with PBS (J), 100 µM etomoxir (K), or 100 µM linoleic acid (L). The fraction of cells in 
S + G2/M phase of the cell cycle decreased by 20% from control levels upon treatment with 100 µM etomoxir (P < .01, 
M); this fraction was unaffected by treatment with linoleic acid (P > .05, M).
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clinical endpoint. Hemorrhage was commonly observed in 
central regions of each tumor; examples of mitotic figures 
and apoptotic nuclei were also observed throughout the 
tumors. Tumors infiltrated tissues surrounding the striatal 
implantation site, including corpus collosum and cortex; 
some of the brain tissues demonstrated invasion of tumor 
cells across midline (Fig. 5 D–J). Mass effect was observed, 
analogous to tumor-related changes in human glioblas-
toma. Sections were also stained to assess KI67+ prolifera-
tion index, p53+ index, and GFAP+ glial content, none of 
which showed significant differences between treatment 
groups (Fig. 5 K–S).
The animals showed similar-sized tumors at clinical 
endpoint since all were subjected to the same euthanasia 
criteria. To evaluate tumor size over the entire experimen-
tal time-course, one animal in each treatment group was 
subjected to MRI over the course of the study (Fig. 6). The 
appearance of glioma using T1-weighted diffusion ten-
sor imaging (without contrast agent) corresponded to the 
emergence of clinical symptoms (eg, weight loss) in both 
animals. Tumor growth occured over the course of approxi-
mately 2 months in control animals (Fig. 6 A–F) and slowed 
upon treatment with 10 mg/kg/day etomoxir (Fig. 6 G–L).
Discussion
The acquisition of a glycolytic strategy is considered a 
hallmark of oncogenic potential in the field of cancer biol-
ogy.19 Reliance upon this biochemical pathway may be 
expected for cells within gliomas as they share morpho-
logical and phenotypic features with glial cells that are 
highly glycolytic and release lactate into the extracellular 
space.20 From a diagnostic imaging perspective, how-
ever, it was not evident that the Warburg effect was regu-
larly manifested in gliomas. Between 35 and 40 percent 
of recurrent gliomas in human patients are not observed 
Fig. 4 Inhibition of fatty acid oxidation by etomoxir prolongs survival time in a syngeneic mouse model of malignant glioma. Fourteen days after 
surgical implantation of glioma-initiating cells into the brains of wild-type adult mice, osmotic pumps were subcutaneously implanted to deliver 
drug or control substance for a period of 30 days in a blinded, placebo-controlled preclinical study (A). Animals were monitored until euthanasia 
criteria were met. Weight loss and other symptoms occurred primarily in the final 3 days of life (B) and were similar between the control and treat-
ment groups (8.0 g vs 7.5 g, respectively, P > .05). Mice treated with 10 mg/kg etomoxir sodium salt lived significantly longer than animals treated 
with vehicle control (C, P < .001, ANOVA).
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using imaging techniques based on glucose uptake (eg, 
FDG-PET), although these tumors can be observed by 
contrast MRI.21,22 Using NMR spectroscopy, Maher et  al 
demonstrated that <50% of the acetyl-CoA pool was 
derived from blood-borne glucose; these results support 
the notion that additional substrates contribute to glioma 
bioenergetic flux.4 Therefore, excess glucose utilization, as 
predicted by the Warburg effect, may not be particularly 
characteristic of gliomas.
A number of studies have investigated the catabolic 
strategies of glioma cells, but technical difficulties have 
challenged efforts to accurately identify the metabolic fuel 
preferences of this tumor type. For example, a high lac-
tate-to-pyruvate ratio has been identified in human glioma 
xenografts in rodents, a finding that seems to support the 
glycolytic nature of glioma.23 However, these results do 
not specifically establish that cells rely upon glycolysis for 
energy metabolism but do demonstrate that ATP levels 
Fig. 5 No difference in tumor size, location, or phenotype was observed between treatment groups at clinical endpoint. Brains from the mice in 
the study were photographed to evaluate tumor severity. (A) No significant difference in tumor volume or macro score was observed between 
treatment groups at clinical endpoint (B–C), corresponding to similar tumor grading by histological assessment (D). Infiltration of tumors from the 
injection site (striatum, E) into corpus collosum (F), cortex (G), dorsal aspects of the brain (H), across midline (I), or into hippocampus (J) were not 
found to be significantly different between treatment groups (P > .05, chi-square test). Tumors were further evaluated to quantify KI67+ prolifera-
tion index (K, N), p53+ malignancy marker (L, O), and GFAP+ glial cell content (M, P) in control-treated animals (K-M) and etomoxir-treated animals 
(N–P). No difference in cellular phenotype was observed between groups (P > .05, 2-tailed t test).
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Fig. 6 Emergence and progression of glioma were delayed upon treatment with the investigational drug etomoxir. Mouse 077 (control) and 
mouse 078 (etomoxir) were subjected to MRI to track tumor progression during the study. Coronal images throughout the brain are shown for 
Mouse 077 across the entire experimental time-course (A-E). At 46 days post cell implantation (DPI), an injection track was observed with no 
evidence of tumor (A). At 53 DPI, there was no evidence of tumor and no clinical symptoms (B). At 67 DPI, a 1.0 mm tumor was observed with no 
clinical symptoms (C). At 72 DPI, a 1.3 mm tumor was observed with approximately 5% loss of body weight the following day (D). At 75 DPI, a 5 mm 
tumor was observed, with approximately 15% loss of body weight and other symptoms signaling clinical endpoint (E). A zoom image of this time 
point is shown (F). Tumor growth was slowed upon treatment with 10 mg/kg/day etomoxir in mouse 078 (G-K). This animal first manifested tumor by 
MR at 95 DPI; at 97 DPI, this animal lost 15% body weight and reached clinical endpoint. A zoom image of this animal's brain at 75 DPI is shown to 
compare with the vehicle-treated animal at the same time point (L).
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remain high despite low hexokinase activity and high lac-
tate secretion; one interpretation of this study could be that 
alternative substrates are being oxidized. Other researchers 
have shown that inhibition of glycolysis with dichloroac-
etate (DHA) decreases proliferation and increases rates of 
apoptotic cell death in primary-cultured glioma cells;24 how-
ever, this drug also decreases the activity of other metabolic 
pathways including fatty acid oxidation.25 Fatty acids have 
previously been shown to inhibit the growth of adult glioma 
cells cultured in the presence of serum,26 an effect thought 
to be mediated by changes in the redox state.27 However, the 
established cell lines and tumor xenografts used for these 
biochemical investigations have been exposed to serum, 
a common cell-culturing protocol that has been shown to 
cause genetic and phenotypic alterations to human glioma 
samples.12
In this study, we report that cells derived from human 
glioma and cultured under optimal conditions express fatty 
acid oxidation enzymes and are dependent upon fatty acid 
oxidation for aerobic respiration and proliferative activity. 
Figure 2 demonstrates that a majority of respiratory activ-
ity arises from fatty acid oxidation, while a smaller subset 
of respiratory activity arises from glucose oxidation. These 
findings are interesting in light of results in humans and 
suggest that much of the acetyl-CoA produced by malignant 
gliomas arises from nonglucose sources.28 Previous studies 
into the metabolic fate of 13C-glucose infused into human 
patients have demonstrated some role for this substrate in 
glioma cell respiration.29 However, radiolabeled fatty acids 
have not been infused for evaluation as a possible alterna-
tive metabolic substrate. We predict that such experiments, 
conducted in mouse models and human patients, will vali-
date our findings by showing that fatty acids are metabolic 
substrates supporting glioma bioenergetics in vivo.
Our findings offer a novel target for the prognosis and treat-
ment of malignant glioma. We tested a specific inhibitor of 
fatty acid oxidation, etomoxir (sodium salt), in the context of 
a blinded, placebo-controlled preclinical study design using 
a clinically relevant mouse model of malignant glioma.16 The 
promising results of etomoxir in slowing tumor growth and 
prolonging survival in this mouse model provide initial evi-
dence for pursuing new therapeutic avenues to target fatty 
acid metabolism in the clinical treatment of astrocytomas.
Etomoxir has already been tested in phase I/II clinical tri-
als for treating moderate congestive heart failure; this trial 
was discontinued because 4 patients (of 226 taking the 
drug) developed unacceptably high liver transaminase lev-
els upon treatment, and the risk of such drastic side effects 
was deemed sufficient to negate the potential benefit of this 
drug for these patients.30 However, the treatment options 
and survival expectancy for patients with malignant glioma 
is much more dire, and the potential benefit in regard to risk 
is very different for patients with this diagnosis. This drug 
may therefore provide promise for clinical therapies aimed 
to slow the growth and progression of malignant glioma.
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